Results 191 to 200 of about 27,891 (313)

Semaglutide Treatment in Young Adults Living With Type 2 Diabetes: A Post Hoc Analysis From the SUSTAIN and PIONEER Clinical Trials

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Young adults (aged ≤ 40 years) are underrepresented in clinical trials that investigate interventions for those living with Type 2 diabetes (T2D). This study evaluated the efficacy of semaglutide treatment in young adults with T2D by examining the effects on HbA1c and body weight (BW) during the SUSTAIN and PIONEER programmes compared to ...
Francesco Zaccardi, Vanita R. Aroda, Ecenur Guder Arslan, Lars Bardtrum, Jonathan Goldney, Erik Ising, Prachi Priyadarshini, Tommy Slater, Melanie J. Davies   +8 more
wiley   +1 more source

Semaglutide-Induced Symptomatic Remission in Ulcerative Colitis. [PDF]

ACG Case Rep J
Alqinai B, Adeniran O, Adekolu A, Gayam S.   +3 more
europepmc   +1 more source

Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Tirzepatide, an injectable glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1) receptor agonist (RA), is approved for weight management in several regions. Oral GLP‐1 RAs, such as semaglutide, are under investigation to improve convenience, acceptance and adherence versus injectable formulations ...
Andreea Ciudin, Erin Johansson, Sarah Zimner‐Rapuch, Georgios K. Dimitriadis, Mathias Hempfling, Laura J. Clark, Ludi Fan, Helene Sapin   +7 more
wiley   +1 more source

Reframing obesity-related HFpEF as a multiorgan syndrome: incretin-based therapies and imaging endpoints. [PDF]

Heart Fail Rev
Mahmod M, Dennis A, Lian J, Langford C, Rahimi K, Wamil M.   +5 more
europepmc   +1 more source

Dietary Strategies and Nutritional Management in Patients Receiving GLP‐1 and Dual GIP/GLP‐1 Receptor Agonists as Adjuncts to Lifestyle Interventions: A Systematic Review of Randomised Clinical Trials

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and dual GIP/GLP‐1 RAs are widely used to manage obesity, prediabetes and type 2 diabetes, typically in combination with lifestyle interventions. Their nutritional implications, however, remain unclear.
Rayanne Santos de Paulo, Dandara Baia Bonifácio, Matheus Henrique Lana de Carvalho, Josefina Bressan   +3 more
wiley   +1 more source

Real-World Cohort Study of Semaglutide in Adults with Type 2 Diabetes Using an Electronic Health Records Database in Tianjin, China. [PDF]

Diabetes Ther
Wang S, Hu P, Shen Z, Chen L.
europepmc   +1 more source

Semaglutide and Cardiovascular Outcomes According to Baseline Aspirin Use: Analyses of the SOUL and SELECT Trials

Diabetes, Obesity and Metabolism, EarlyView.
Dirk Müller‐Wieland, Darren K. McGuire, A. Michael Lincoff, John B. Buse, Johannes F. E. Mann, Silvio E. Inzucchi, Rodica Pop‐Busui, Sharon L. Mulvagh, Scott S. Emerson, Neil R. Poulter, John E. Deanfield, Nikolaus Marx   +11 more
wiley   +1 more source

Hyperaldosteronism in the Pathophysiology and Management of Cardiovascular‐Kidney‐Metabolic Syndrome

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Cardiovascular‐kidney‐metabolic (CKM) syndrome is defined by the pathologic interconnections between obesity, diabetes, chronic kidney disease and cardiovascular disease. An important and underrecognized pathophysiologic factor underlying CKM syndrome is obesity‐induced aldosterone excess.
Evan Zeitler, Klara R. Klein, Ildiko Lingvay, Anthony Pick, Liana K. Billings   +4 more
wiley   +1 more source

Pharmacokinetic Bioequivalence of Orforglipron Tablets and Capsules in Healthy Participants With Obesity or Overweight

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To evaluate the bioequivalence of orally administered orforglipron tablets and capsules in participants with obesity or overweight who were otherwise healthy. Materials and Methods This phase 1, multicenter, open‐label, multiple‐dose, dose‐escalation study was conducted in 429 healthy adults.
Xiaosu Ma, Ying Grace Li, Sohini Raha, David C. Sperry, David E. Coutant, Shobha Bhattachar   +5 more
wiley   +1 more source

Oral Glucagon-Like Peptide-1 Receptor Agonists for Preventing Cardiorenal Complications. [PDF]

Curr Cardiol Rep
Odeleye V, Singh N, Gautam S, Shannon E, Bibb WM, McClure M, Paul TK.   +6 more
europepmc   +1 more source